Value of strain and strain rate imaging in predicting adverse outcomes in patients with chronic pulmonary arterial hypertension

2008 ◽  
Vol 7 ◽  
pp. 106-106
Author(s):  
H UTSUNOMIYA ◽  
S NAKATANI ◽  
M NISHIHIRA ◽  
T OKADA ◽  
H KANZAKI ◽  
...  
Author(s):  
Wen Zhang ◽  
Mengyuan Yang ◽  
Mei Peng ◽  
Yanling Ding

Background: Pregnant women with pulmonary arterial hypertension associated with congenital heart diseases (PAH-CHD) have a high incidence of mortality and adverse outcomes for mother and child. Methods: We retrospectively examined the treatment strategies and analyzed the outcomes of pregnancy in patients with pulmonary arterial hypertension managed at a single clinical hospital from 2009 to 2018. Results: Analysis of all 102 patients with PAH-CHD in pregnancy showed that maternal and newborn death from the disease was low(<3%, 3/102) compared to rates previously reported. Although patients with mild pulmonary hypertension can deliver safely, those with moderate to severe pulmonary artery pressure (PAP), and high functional class tend to have a high risk of heart failure. Medications were selectively administered to patients with more severe disease, and it was, therefore, challenging to make a universal statement on their benefit, but they appear having some benefits in improving birth outcomes for mother and child. While some treatments such as anticoagulant therapy during pregnancy, and oxytocin after delivery, did not improve the health outcome of pregnant women but seemed to provide some benefits to the newborns. Conclusion: Our retrospective analysis of existing clinical data provides preliminary results for further studies to formally evaluate the efficacy of clinical management of patients with pulmonary arterial hypertension.


Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Aylin Tugcu ◽  
Ozlem Yildirimturk ◽  
Yelda Tayyareci ◽  
I C Demiroglu ◽  
Saide Aytekin

To evaluate regional right ventricular (RV) myocardial velocity, strain and strain rate alterations in newly diagnosed obstructive sleep apnea (OSA) patients without systemic and pulmonary arterial hypertension and to correlate OSA severity to RV dysfunction using Velocity Vector Imaging (VVI). The OSA group consisted of 27 obese patients who were found to have moderate-to-severe OSA, and the control group of 26 age and body mass index-matched healthy subjects who were found not to have OSA on their first polysomnographic testing. All subjects underwent 24-hour ambulatory blood pressure monitoring and conventional echocardiography to exclude systemic and pulmonary arterial hypertension. Peak systolic myocardial velocities, strain and strain rates were determined at the basal and mid segments of RV free wall by VVI. Systemic and pulmonary artery pressures were within normal limits in both groups. Peak systolic myocardial velocities, strain and strain rates were significantly impaired in patients with OSA compared to controls (Table 1 ). The apnea hypopnea index (AHI) correlated strongly with all indices obtained by VVI (basal velocity: r=−0.563, p<0.001; basal strain: r=−0.587, p<0.001;basal strain rate: r=−0.372, p<0.006, mid velocity: r=−0.559, p<0.001, mid strain: r=−0.689, p<0.001;mid strain rate: r=−0.658, p<0.001). The structural consequences of OSA in the RV is influenced by the severity of AHI. These effects occur independently from obesity and systemic hypertension. VVI can accurately recognize and quantify abnormalities of RV function in these subgroup of patients. Table 1


2014 ◽  
Vol 7 (6) ◽  
pp. 903-910 ◽  
Author(s):  
Thenappan Thenappan ◽  
Samit S. Roy ◽  
Sue Duval ◽  
Cherylanne Glassner-Kolmin ◽  
Mardi Gomberg-Maitland

2020 ◽  
Vol 10 (4) ◽  
pp. 204589402094728
Author(s):  
Argen Mamazhakypov ◽  
Astrid Weiß ◽  
Sven Zukunft ◽  
Akylbek Sydykov ◽  
Baktybek Kojonazarov ◽  
...  

Pulmonary arterial hypertension is a severe respiratory disease characterized by pulmonary artery remodeling. RV dysfunction and dysregulated circulating metabolomics are associated with adverse outcomes in pulmonary arterial hypertension. We investigated effects of tadalafil and macitentan alone or in combination on the RV and plasma metabolomics in SuHx and PAB models. For SuHx model, rats were injected with SU5416 and exposed to hypoxia for three weeks and then were returned to normoxia and treated with either tadalafil (10 mg/kg in chow) or macitentan (10 mg/kg in chow) or their combination (both 10 mg/kg in chow) for two weeks. For PAB model, rats were subjected to either sham or PAB surgery for three weeks and treated with above-mentioned drugs from week 1 to week 3. Following terminal echocardiographic and hemodynamic measurements, tissue samples were collected for metabolomic, histological and gene expression analysis. Both SuHx and PAB rats developed RV remodeling/dysfunction with severe and mild plasma metabolomic alterations, respectively. In SuHx rats, tadalafil and macitentan alone or in combination improved RV remodeling/function with the effects of macitentan and combination therapy being superior to tadalafil. All therapies similarly attenuated SuHx-induced changes in plasma metabolomics. In PAB rats, only macitentan improved RV remodeling/function, while only tadalafil attenuated PAB-induced changes in plasma metabolomics.


Sign in / Sign up

Export Citation Format

Share Document